Ionis Pharmaceuticals, Inc. company information, Employees & Contact Information

Ionis to present at upcoming investor conferences PR Newswire

Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases Biogen

Isis Pharmaceuticals becomes Ionis Pharmaceuticals European Pharmaceutical Review

Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases PR Newswire

Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy Biogen

Ionis announces the appointment of Michael Yang to Board of Directors PR Newswire

Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology PR Newswire

Ionis Pharmaceuticals Announces Publication in Nature Biotechnology of a Novel Mechanism of Action for Antisense Drugs That Significantly Expands Therapeutic Opportunities PR Newswire

Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema PR Newswire

Ionis Pharmaceuticals to Present at Upcoming Investor Conferences PR Newswire

Ionis' pioneering antisense technology to be featured in multiple presentations at American Heart Association (AHA) Scientific Sessions 2020 PR Newswire

Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome PR Newswire

Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II Conference PR Newswire

Ionis Pharmaceuticals and MD Anderson Form Strategic Alliance to Advance Novel Cancer Therapeutics PR Newswire

Ionis Pharmaceuticals Supports Rare Disease Day PR Newswire

Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development PR Newswire

Ionis partners with Metagenomi to add gene editing to its broad technology platform PR Newswire

Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease PR Newswire

Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome PR Newswire

Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy PR Newswire

Ionis Pharmaceuticals Earns $5 Million Milestone Payment from Biogen for Advancing a New Program Under Its Broad Neurology Strategic Collaboration PR Newswire

Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics PR Newswire

Ionis Closes Strategic Collaboration with Biogen to Develop Drugs for a Broad Range of Neurological Diseases PR Newswire

Ionis to present at upcoming investor conference (2023-07-05) Seeking Alpha

Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics PR Newswire

Ionis Enters New Collaboration with Partner to Develop IONIS-FB-L Rx for Complement-Mediated Diseases PR Newswire

IONIS-HTT Rx (RG6042) Granted PRIME Designation by the European Medicines Agency for the Treatment of People with Huntington's Disease PR Newswire

Ionis and Akcea Close on Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx PR Newswire

Ionis announces GSK has advanced bepirovirsen into Phase 3 development European AIDS Treatment Group

Ionis Pharmaceuticals Licenses First Oral Antisense Drug Acting Locally in the GI Tract to Janssen PR Newswire

Akcea Therapeutics Receives Orphan Designation in Europe for Volanesorsen for the Treatment of Familial Partial Lipodystrophy (FPL) PR Newswire

Ionis Earns $40 Million SPINRAZA Regulatory Milestone Payment from Biogen PR Newswire

Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events PR Newswire

Ionis announces enrollment completion of Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen PR Newswire

Isis Pharmaceuticals to change its name Ionis Pharmaceuticals CNBC

Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy Biogen

Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema PR Newswire

FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides Mary Ann Liebert, Inc.

Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference The Malaysian Reserve